Lecanemab SC
Alzheimer's Disease
Phase 3Active (Study 302)
Key Facts
About BioArctic AB
BioArctic is a publicly traded Swedish biotech company at the forefront of developing novel treatments for neurodegenerative disorders. Its most significant achievement is the co-development of lecanemab (Leqembi®) with Eisai, which became the first amyloid-targeting therapy to receive traditional FDA approval for Alzheimer's disease. The company leverages its proprietary BrainTransporter® technology to develop antibodies and other biologics that can cross the blood-brain barrier, with a pipeline extending beyond Alzheimer's to Parkinson's disease and other CNS conditions. BioArctic's strategy combines proprietary research with strategic partnerships to advance its clinical programs.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Undisclosed Program | uniQure | Preclinical |
| NVG-291 | NervGen Pharma | Phase 1b/2a |